RANEXA

This brand name is authorized in Austria, Cyprus, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Italy, Lithuania, New Zealand, Poland, Romania, Singapore, United Kingdom, United States

Active ingredients

The drug RANEXA contains one active pharmaceutical ingredient (API):

1 Ranolazine UNII A6IEZ5M406 - RANOLAZINE

Ranolazine may have some antianginal effects by inhibition of the late sodium current in cardiac cells. This reduces intracellular sodium accumulation and consequently decreases intracellular calcium overload. Ranolazine, via its action to decrease the late sodium current, is considered to reduce these intracellular ionic imbalances during ischaemia. This reduction in cellular calcium overload is expected to improve myocardial relaxation and thereby decrease left ventricular diastolic stiffness. Read about Ranolazine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RANEXA Prolonged-release tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C01EB18	Ranolazine	C Cardiovascular system → C01 Cardiac therapy → C01E Other cardiac preparations → C01EB Other cardiac preparations
Discover more medicines within C01EB18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1361652, 1361674, 1361685, 1405550, 1405561, 1405572, 1405583, 1405594, 1405606
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 08462001, 08462003, 08462005
Country: FR	Base de données publique des médicaments	Identifier(s): 60922794, 63170891, 64679592
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 149980, 149987, 149990, 375322, 377000, 377002, 377004, 381645, 381647, 381649
Country: HK	Department of Health Drug Office	Identifier(s): 63607, 63608, 63609
Country: IE	Health Products Regulatory Authority	Identifier(s): 43250, 43252, 43254, 43262, 43263
Country: IT	Agenzia del Farmaco	Identifier(s): 038917011, 038917023, 038917035, 038917047, 038917050, 038917062, 038917074, 038917086, 038917098, 038917100, 038917112, 038917124
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1033655, 1033656, 1033657, 1033658, 1033659, 1033660, 1056094, 1056095, 1056096, 1056097, 1056098, 1056099
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 17366, 17384, 17385
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100145586, 100214910, 100214927
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W55083001, W55083002, W55083003, W55083004, W55084001, W55084002, W55084003, W55084004, W55085001, W55085002, W55085003, W55085004
Country: SG	Health Sciences Authority	Identifier(s): 14861P, 14862P, 14863P
Country: US	FDA, National Drug Code	Identifier(s): 43353-880, 61958-1003, 61958-1004